Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 24 FE versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 24 FE versus OGESTREL 0 5 50 21.
GILDESS 24 FE vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone provides contraceptive effect primarily by suppression of gonadotropins (FSH and LH), inhibition of ovulation, and alterations in cervical mucus and endometrium. Drospirenone has antimineralocorticoid activity and antiandrogenic properties.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
One tablet orally once daily for 24 days, followed by 4 days of placebo (iron tablets). The active tablets contain 0.8 mg norethindrone acetate and 0.025 mg ethinyl estradiol.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours); drospirenone: terminal half-life ~30-40 hours (mean ~32 hours). Clinical context: Steady-state achieved within 10 days for both components.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Renal: ~50-60% as metabolites (ethinyl estradiol glucuronide and sulfate conjugates, drospirenone metabolites); fecal: ~40-50% (drospirenone metabolites); biliary excretion contributes to enterohepatic circulation.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive